New advances in immunotherapy for non-small cell lung cancer

被引：4

作者：

Qin, Haifeng ^{[1
]}

Wang, Fang ^{[1
]}

Liu, Hui ^{[1
]}

Zeng, Zhen ^{[1
]}

Wang, Shasha ^{[1
]}

Pan, Xin ^{[1
]}

Gao, Hongjun ^{[1
]}

机构：

[1] 307th Hosp Chinese Peoples Liberat Army, Dept Lung Canc, 8 East St, Beijing 100071, Peoples R China

来源：

AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH | 2018年 / 10卷 / 08期

关键词：

PD-1/PD-L1; CTLA-4; NSCLC; immunotherapy; biomarkers; OPEN-LABEL; PHASE-III; INHIBITORY RECEPTORS; 1ST-LINE TREATMENT; MOLECULAR-BASIS; DOUBLE-BLIND; MULTICENTER; DOCETAXEL; BLOCKADE; SAFETY;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunotherapy is one of the methods that can change the survival rate of patients with malignant tumors, in addition to surgery therapy, radiotherapy, chemotherapy and targeted therapy. Among various immunotherapy methods, immunoprecipitation inhibitors have been the most effective medications developed in recent years. At present, more in-depth studies have been conducted for two immune checkpoint inhibitor pathways, programmed cell death protein 1 (PD-1)/Programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and a variety of medications for those above mentioned. The present study briefly reviews the results of clinical trials for relevant immune checkpoint inhibitors in lung cancer.

引用

页码：2234 / 2245

页数：12

共 58 条

[1] Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].

Anderson, Ana C. ;

Joller, Nicole ;

Kuchroo, Vijay K. .

IMMUNITY, 2016, 44 (05) :989-1004

[2] Human mismatch repair system balances mutation rates between strands by removing more mismatches from the lagging strand [J].

Andrianova, Maria A. ;

Bazykin, Georgii A. ;

Nikolaev, Sergey I. ;

Seplyarskiy, Vladimir B. .

GENOME RESEARCH, 2017, 27 (08) :1336-1343

[3]

[Anonymous], J CLIN ONCOL

[4] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[5] Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) [J].

Antonia, Scott ;

Rizvi, Naiyer ;

Brahmer, Julie ;

Ou, Sai-Hong ;

Khleif, Samir N. ;

Hwu, Wen-Jen ;

Gutierrez, Martin ;

Schoffski, Patrick ;

Hamid, Omid ;

Weiss, Jared ;

Lutzky, Jose ;

Maio, Michele ;

Nemunaitis, John ;

Jaeger, Dirk ;

Balmanoukian, Ani ;

Rebelatto, Marlon C. ;

Steele, Keith E. ;

Jin, Xiaoping ;

Robbins, Paul B. ;

Blake-Haskins, John A. ;

Segal, Neil H. .

CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)

[6] Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection [J].

Blackburn, Shawn D. ;

Shin, Haina ;

Haining, W. Nicholas ;

Zou, Tao ;

Workman, Creg J. ;

Polley, Antonio ;

Betts, Michael R. ;

Freeman, Gordon J. ;

Vignali, Dario A. A. ;

Wherry, E. John .

NATURE IMMUNOLOGY, 2009, 10 (01) :29-37

[7] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[8] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[9] Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management [J].

Colli, Leandro M. ;

Machiela, Mitchell J. ;

Zhang, Han ;

Myers, Timothy A. ;

Jessop, Lea ;

Delattre, Olivier ;

Yu, Kai ;

Chanock, Stephen J. .

CANCER RESEARCH, 2017, 77 (13) :3666-3671

[10] Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma [J].

Dong, Zhong-Yi ;

Zhong, Wen-Zhao ;

Zhang, Xu-Chao ;

Su, Jian ;

Xie, Zhi ;

Liu, Si-Yang ;

Tu, Hai-Yan ;

Chen, Hua-Jun ;

Sun, Yue-Li ;

Zhou, Qing ;

Yang, Jin-Ji ;

Yang, Xue-Ning ;

Lin, Jia-Xin ;

Yan, Hong-Hong ;

Zhai, Hao-Ran ;

Yan, Li-Xu ;

Liao, Ri-Qiang ;

Wu, Si-Pei ;

Wu, Yi-Long .

CLINICAL CANCER RESEARCH, 2017, 23 (12) :3012-3024

← 1 2 3 4 5 6 →